Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth factor receptors such as human epidermal growth factor receptor 2 (...

Full description

Bibliographic Details
Main Authors: Javier A. Menendez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyàs, Bharvi P. Oza-Gajera, Sara Verdura, Ingrid Espinoza, Luciano Vellon, Inderjit Mehmi, Ruth Lupu
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
fatty acid synthase
endocrine resistance
tamoxifen
estrogen receptor
HER2
Online Access:https://www.mdpi.com/2072-6694/13/5/1132

Internet

https://www.mdpi.com/2072-6694/13/5/1132

Similar Items